IRadimed Co. (NASDAQ:IRMD) Director James B. Hawkins Sells 6,038 Shares

IRadimed Co. (NASDAQ:IRMD) Director James B. Hawkins sold 6,038 shares of the company’s stock in a transaction dated Tuesday, November 23rd. The shares were sold at an average price of $41.20, for a total transaction of $248,765.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ:IRMD opened at $43.00 on Thursday. The firm has a 50 day simple moving average of $36.45 and a 200-day simple moving average of $33.38. The firm has a market cap of $530.71 million, a PE ratio of 89.58 and a beta of 0.90. IRadimed Co. has a 1-year low of $21.65 and a 1-year high of $45.01.

IRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Thursday, October 28th. The medical equipment provider reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. IRadimed had a net margin of 15.77% and a return on equity of 9.44%. During the same period last year, the firm earned $0.09 earnings per share. Equities analysts expect that IRadimed Co. will post 0.62 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in IRadimed by 62.2% during the second quarter. Vanguard Group Inc. now owns 489,913 shares of the medical equipment provider’s stock worth $14,408,000 after purchasing an additional 187,953 shares during the last quarter. BlackRock Inc. increased its position in IRadimed by 2.9% during the third quarter. BlackRock Inc. now owns 416,845 shares of the medical equipment provider’s stock worth $14,002,000 after purchasing an additional 11,833 shares during the last quarter. Geode Capital Management LLC increased its position in IRadimed by 5.4% during the third quarter. Geode Capital Management LLC now owns 101,659 shares of the medical equipment provider’s stock worth $3,414,000 after purchasing an additional 5,176 shares during the last quarter. State Street Corp increased its position in IRadimed by 5.5% during the second quarter. State Street Corp now owns 96,438 shares of the medical equipment provider’s stock worth $2,836,000 after purchasing an additional 4,993 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in IRadimed by 33.9% during the third quarter. Dimensional Fund Advisors LP now owns 87,684 shares of the medical equipment provider’s stock worth $2,946,000 after purchasing an additional 22,190 shares during the last quarter. 39.18% of the stock is owned by hedge funds and other institutional investors.

Several analysts have issued reports on the stock. TheStreet raised shares of IRadimed from a “c+” rating to a “b” rating in a report on Friday, July 30th. Zacks Investment Research raised shares of IRadimed from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Thursday, November 4th. Finally, Roth Capital boosted their price objective on shares of IRadimed from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 2nd.

IRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

See Also: Liquidity

Insider Buying and Selling by Quarter for IRadimed (NASDAQ:IRMD)

Receive News & Ratings for IRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRadimed and related companies with MarketBeat.com's FREE daily email newsletter.